{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:02:31Z","timestamp":1789617751898,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40121-026-01332-5","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T18:59:50Z","timestamp":1774637990000},"page":"1401-1424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022\u20132023"],"prefix":"10.1007","volume":"15","author":[{"given":"Wilhelmine","family":"Meeraus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Carty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabada","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael A.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Goios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahila","family":"Justo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Quint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"1","key":"1332_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(18)30496-X","volume":"7","author":"GBD 2017 Influenza Collaborators","year":"2019","unstructured":"GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2019;7(1):69\u201389. https:\/\/doi.org\/10.1016\/S2213-2600(18)30496-X.","journal-title":"Lancet Respir Med"},{"key":"1332_CR2","unstructured":"Centers for Disease Control and Prevention. People at Increased Risk for Flu Complications. 2024 10 April 2025; https:\/\/www.cdc.gov\/flu\/highrisk\/index.htm."},{"issue":"4","key":"1332_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jinf.2013.11.013","volume":"68","author":"D Cromer","year":"2014","unstructured":"Cromer D, van Hoek AJ, Jit M, et al. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy. J Infect. 2014;68(4):363\u201371. https:\/\/doi.org\/10.1016\/j.jinf.2013.11.013.","journal-title":"J Infect"},{"issue":"10","key":"1332_CR4","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1093\/cid\/ciz638","volume":"70","author":"JP Collins","year":"2020","unstructured":"Collins JP, Campbell AP, Openo K, et al. Outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011-2015. Clin Infect Dis. 2020;70(10):2121\u201330. https:\/\/doi.org\/10.1093\/cid\/ciz638.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1332_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac664","volume":"10","author":"P Kim","year":"2023","unstructured":"Kim P, Coleman B, Kwong JC, et al. Burden of severe illness associated with laboratory-confirmed influenza in adults aged 50\u201364 years, 2010\u20132011 to 2016\u20132017. Open Forum Infect Dis. 2023;10(1):ofac664. https:\/\/doi.org\/10.1093\/ofid\/ofac664.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"1332_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s1473-3099(09)70175-6","volume":"9","author":"KM Kunisaki","year":"2009","unstructured":"Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8):493\u2013504. https:\/\/doi.org\/10.1016\/s1473-3099(09)70175-6.","journal-title":"Lancet Infect Dis"},{"key":"1332_CR7","unstructured":"World Health Organization. Global Influenza Programme. 2025 10 April 2025]; https:\/\/www.who.int\/teams\/global-influenza-programme\/vaccines."},{"key":"1332_CR8","unstructured":"UK Health and Security Agency. Influenza: the green book, chapter 19. 2023 9 April 2025]; https:\/\/www.gov.uk\/government\/publications\/influenza-the-green-book-chapter-19."},{"key":"1332_CR9","unstructured":"UK government. Annual flu programme. 2025 10 April 2025]; Available from: https:\/\/www.gov.uk\/government\/collections\/annual-flu-programme."},{"issue":"11","key":"1332_CR10","doi-asserted-by":"publisher","first-page":"e1612","DOI":"10.1016\/S2214-109X(22)00358-8","volume":"10","author":"ST Ali","year":"2022","unstructured":"Ali ST, Lau YC, Shan S, et al. Prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic: a modelling study. Lancet Glob Health. 2022;10(11):e1612\u201322. https:\/\/doi.org\/10.1016\/S2214-109X(22)00358-8.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"1332_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2056399","volume":"18","author":"M Ashraf","year":"2022","unstructured":"Ashraf M, Rajaram S, English PM. How the COVID 19 pandemic will shape influenza public health initiatives: the UK experience. Hum Vaccin Immunother. 2022;18(5):2056399. https:\/\/doi.org\/10.1080\/21645515.2022.2056399.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1332_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29402-5","volume":"13","author":"V Dhanasekaran","year":"2022","unstructured":"Dhanasekaran V, Sullivan S, Edwards KM, et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination. Nat Commun. 2022;13(1):1721. https:\/\/doi.org\/10.1038\/s41467-022-29402-5.","journal-title":"Nat Commun"},{"key":"1332_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/14737167.2024.2427307","volume":"25","author":"C de Courville","year":"2024","unstructured":"de Courville C, Bricout H, Alvarez FP, et al. Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 - 2020. Expert Rev Pharmacoecon Outcomes Res. 2024;25:385\u201397. https:\/\/doi.org\/10.1080\/14737167.2024.2427307.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1332_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100747","volume":"35","author":"RA Evans","year":"2023","unstructured":"Evans RA, Dube S, Lu Y, et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. The Lancet Regional Health - Europe. 2023;35:100747. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100747.","journal-title":"The Lancet Regional Health - Europe"},{"issue":"3","key":"1332_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106432","volume":"90","author":"JK Quint","year":"2025","unstructured":"Quint JK, Dube S, Carty L, et al. Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study. J Infect. 2025;90(3):106432. https:\/\/doi.org\/10.1016\/j.jinf.2025.106432.","journal-title":"J Infect"},{"key":"1332_CR16","unstructured":"World Health Organization. Coronavirus disease (COVID-19): Similarities and differences between COVID-19 and Influenza. 2024 3 July 2025]; https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/coronavirus-disease-covid-19-similarities-and-differences-with-influenza."},{"key":"1332_CR17","unstructured":"NHS England. General Practice Extraction Service (GPES) Data for pandemic planning and research: a guide for analysts and users of the data. 2024 [cited 2024 19 August]; https:\/\/digital.nhs.uk\/coronavirus\/gpes-data-for-pandemic-planning-and-research\/guide-for-analysts-and-users-of-the-data."},{"issue":"4","key":"1332_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5788","volume":"33","author":"K Benack","year":"2024","unstructured":"Benack K, Nyandege A, Nonnenmacher E, et al. Validity of ICD-10-based algorithms to identify patients with influenza in inpatient and outpatient settings. Pharmacoepidemiol Drug Saf. 2024;33(4):e5788. https:\/\/doi.org\/10.1002\/pds.5788.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1332_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244746","volume":"16","author":"MA Hamilton","year":"2021","unstructured":"Hamilton MA, Calzavara A, Emerson SD, et al. Validating International Classification of Disease 10th Revision algorithms for identifying influenza and respiratory syncytial virus hospitalizations. PLoS ONE. 2021;16(1):e0244746. https:\/\/doi.org\/10.1371\/journal.pone.0244746.","journal-title":"PLoS ONE"},{"issue":"1","key":"1332_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-021-01531-9","volume":"21","author":"N Wabe","year":"2021","unstructured":"Wabe N, Li L, Lindeman R, et al. Evaluation of the accuracy of diagnostic coding for influenza compared to laboratory results: The availability of test results before hospital discharge facilitates improved coding accuracy. BMC Med Inform Decis Mak. 2021;21(1):168. https:\/\/doi.org\/10.1186\/s12911-021-01531-9.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"5","key":"1332_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a038711","volume":"11","author":"RC Mettelman","year":"2021","unstructured":"Mettelman RC, Thomas PG. Human susceptibility to influenza infection and severe disease. Cold Spring Harb Perspect Med. 2021;11(5):a038711. https:\/\/doi.org\/10.1101\/cshperspect.a038711.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"1332_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/cid\/ciad627","volume":"78","author":"S Carazo","year":"2023","unstructured":"Carazo S, Guay C-A, Skowronski DM, et al. Influenza hospitalization burden by subtype, age, comorbidity, and vaccination status: 2012\u20132013 to 2018\u20132019 seasons, Quebec, Canada. Clin Infect Dis. 2023;78(3):765\u201374. https:\/\/doi.org\/10.1093\/cid\/ciad627.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1332_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2164215","volume":"12","author":"JH Hwang","year":"2023","unstructured":"Hwang JH, You YS, Yeom SW, et al. Influenza viral infection is a risk factor for severe illness in COVID-19 patients: A nationwide population-based cohort study. Emerg Microbes Infect. 2023;12(1):2164215. https:\/\/doi.org\/10.1080\/22221751.2022.2164215.","journal-title":"Emerg Microbes Infect"},{"key":"1332_CR24","unstructured":"UK Health and Security Agency. Surveillance of influenza and other seasonal respiratory viruses in the UK, winter 2022 to 2023. 2024 30 April 2025]; https:\/\/www.gov.uk\/government\/statistics\/annual-flu-reports\/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-the-uk-winter-2022-to-2023."},{"issue":"11","key":"1332_CR25","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/cid\/ciac296","volume":"75","author":"S Kamidani","year":"2022","unstructured":"Kamidani S, Garg S, Rolfes MA, et al. Epidemiology, clinical characteristics, and outcomes of influenza-associated hospitalizations in US children over 9 seasons following the 2009 H1N1 pandemic. Clin Infect Dis. 2022;75(11):1930\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac296.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1332_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/cid\/cit725","volume":"58","author":"MJ Memoli","year":"2013","unstructured":"Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis. 2013;58(2):214\u201324. https:\/\/doi.org\/10.1093\/cid\/cit725.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1332_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jinf.2023.11.001","volume":"88","author":"T Chen","year":"2024","unstructured":"Chen T, Wang H, Lin H, et al. Estimating the prevalence of immunocompromising conditions and primary immunodeficiency disorders in the Chinese population. J Infect. 2024;88(1):63\u20134. https:\/\/doi.org\/10.1016\/j.jinf.2023.11.001.","journal-title":"J Infect"},{"issue":"5","key":"1332_CR28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00109-022-02193-4","volume":"100","author":"A Salminen","year":"2022","unstructured":"Salminen A. Clinical perspectives on the age-related increase of immunosuppressive activity. J Mol Med (Berl). 2022;100(5):697\u2013712. https:\/\/doi.org\/10.1007\/s00109-022-02193-4.","journal-title":"J Mol Med (Berl)"},{"key":"1332_CR29","unstructured":"UK Health and Security Agency. Seasonal influenza vaccine uptake in children of school age in England: winter season 2023 to 2024. 2024 18 November 2024 16 April 2025]; https:\/\/www.gov.uk\/government\/statistics\/seasonal-influenza-vaccine-uptake-in-children-of-school-age-winter-season-2023-to-2024\/seasonal-influenza-vaccine-uptake-in-children-of-school-age-in-england-winter-season-2023-to-2024."},{"issue":"1","key":"1332_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjph-2024-000929","volume":"2","author":"B Kasstan","year":"2024","unstructured":"Kasstan B, Lazarus R, Ali I, et al. Improving influenza vaccine uptake in clinical risk groups: Patient, provider and commissioner perspectives on the acceptability and feasibility of expanding delivery pathways in England. BMJ Public Health. 2024;2(1):e000929. https:\/\/doi.org\/10.1136\/bmjph-2024-000929.","journal-title":"BMJ Public Health"},{"key":"1332_CR31","unstructured":"National Institute for Health and Care Excellence. Flu vaccination: increasing uptake (NICE guideline NG103). 2018 22 August 2018 23 April 2025]; https:\/\/www.nice.org.uk\/guidance\/ng103."},{"issue":"3","key":"1332_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000851","volume":"2","author":"LJ Dexter","year":"2012","unstructured":"Dexter LJ, Teare MD, Dexter M, et al. Strategies to increase influenza vaccination rates: outcomes of a nationwide cross-sectional survey of UK general practice. BMJ Open. 2012;2(3):e000851. https:\/\/doi.org\/10.1136\/bmjopen-2011-000851.","journal-title":"BMJ Open"},{"issue":"25","key":"1332_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.06.059","volume":"42","author":"AH Kafadar","year":"2024","unstructured":"Kafadar AH, Sabatini S, Jones KA, et al. Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: a systematic review and meta-analysis. Vaccine. 2024;42(25):126092. https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.059.","journal-title":"Vaccine"},{"key":"1332_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076542","volume":"384","author":"K Ruggeri","year":"2024","unstructured":"Ruggeri K, Vanderslott S, Yamada Y, et al. Behavioural interventions to reduce vaccine hesitancy driven by misinformation on social media. BMJ. 2024;384:e076542. https:\/\/doi.org\/10.1136\/bmj-2023-076542.","journal-title":"BMJ"},{"issue":"Suppl 4","key":"1332_CR35","first-page":"19","volume":"19","author":"BJ Cowling","year":"2013","unstructured":"Cowling BJ, Chan KH, Peiris JS, et al. Viral shedding, clinical history and transmission of influenza. Hong Kong Med J. 2013;19(Suppl 4):19\u201323.","journal-title":"Hong Kong Med J"},{"issue":"3","key":"1332_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106443","volume":"90","author":"KV Williams","year":"2025","unstructured":"Williams KV, Krauland MG, Nowalk MP, et al. Increasing child vaccination coverage can reduce influenza cases across age groups: an agent-based modeling study. J Infect. 2025;90(3):106443. https:\/\/doi.org\/10.1016\/j.jinf.2025.106443.","journal-title":"J Infect"},{"issue":"3","key":"1332_CR37","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1093\/cid\/ciae547","volume":"80","author":"AC O'Halloran","year":"2025","unstructured":"O\u2019Halloran AC, Millman AJ, Holstein R, et al. The burden of all-cause mortality following influenza-associated hospitalizations: Influenza Hospitalization Surveillance Network, 2010-2019. Clin Infect Dis. 2025;80(3):e43\u20135. https:\/\/doi.org\/10.1093\/cid\/ciae547.","journal-title":"Clin Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01332-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01332-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01332-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:34:12Z","timestamp":1777484052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01332-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1332"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01332-5","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wilhelmine Meeraus, Sudhir Venkatesan and Sabada Dube are employees of, and may hold stock and\/or stock options in, AstraZeneca. Lucy Carty is an employee of SRG Recruitment; and was contracted to AstraZeneca for this analysis. Sylvia Taylor is a former employee of AstraZeneca and may hold stock\/and or stock options. Ana Goios is an employee of, and holds shares in, P95, which received a consultancy fee for the conduct of the current study from AstraZeneca. Kathryn Evans, Nahila Justo and Yi Lu are employees of Thermo Fisher Scientific, which received funding for the conduct of the current study (data acquisition and analysis) from AstraZeneca. Rachael A. Evans reports receiving funding from AstraZeneca for providing advice during the development of the INFORM study, research grants from National Institute for Health and Care Research, UK Research and Innovation, Wolfson Foundation, and Genentech\/Roche to her institution for works not related to current manuscript, non-promotional speaker fees from Boehringer Ingelheim and Moderna, and serving non-paid as European Respiratory Society Group 01.02 Pulmonary Rehabilitation and Chronic Care Chair and American Thoracic Society Pulmonary Rehabilitation Assembly Chair. Jennifer K. Quint reports receiving funding from AstraZeneca for providing advice throughout the current study, research grants from the Medical Research Council, Health Data Research UK, GSK, Boehringer Ingelheim, Asthma\u2009+\u2009Lung UK, and AstraZeneca to her research institution, and consulting fees from GSK, Evidera, AstraZeneca, and Insmed. Lance Turtle has received consulting fees from Medicines and Healthcare products Regulatory Agency and Bavarian Nordic, and speaker fees from Eisai Ltd., Medscape, and the Primary Care Cardiovascular society. He has received consulting fees from AstraZeneca, Synairgen, and GeoVax, paid to the University of Liverpool and support for conference attendance from AstraZeneca. Lance Turtle is supported by the US Food and Drug Administration Medical Countermeasures Initiative contract 75F40120C00085, and the National Institute for Health Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections (NIHR207393) at University of Liverpool in partnership the UK Health Security Agency (UKHSA), in collaboration with Liverpool School of Tropical Medicine and University of Oxford. Lance Turtle is based at University of Liverpool. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health, or UKHSA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Access to anonymised data was facilitated through the NHS England Secure Data Environment. All analyses were conducted in the secure environment without any personal data transfer. The study protocol was exempted from Ethics Application by the Health Research Authority under the Integrated Research Application System application number 304305. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}